Big Pharma Split Stock Fundamentals
| PRM Stock | CAD 13.30 0.18 1.37% |
Big Pharma Split fundamentals help investors to digest information that contributes to Big Pharma's financial success or failures. It also enables traders to predict the movement of Big Stock. The fundamental analysis module provides a way to measure Big Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Big Pharma stock.
At this time, Big Pharma's Depreciation And Amortization is very stable compared to the past year. As of the 1st of December 2024, Other Operating Expenses is likely to grow to about 495.3 K, while Selling General Administrative is likely to drop about 308.6 K. Big | Select Account or Indicator |
Big Pharma Split Company Return On Equity Analysis
Big Pharma's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Big Pharma Return On Equity | -0.0363 |
Most of Big Pharma's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Big Pharma Split is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Big Return On Equity Driver Correlations
Understanding the fundamental principles of building solid financial models for Big Pharma is extremely important. It helps to project a fair market value of Big Stock properly, considering its historical fundamentals such as Return On Equity. Since Big Pharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Big Pharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Big Pharma's interrelated accounts and indicators.
Click cells to compare fundamentals
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Big Total Stockholder Equity
Total Stockholder Equity |
|
Based on the latest financial disclosure, Big Pharma Split has a Return On Equity of -0.0363. This is 102.5% lower than that of the Capital Markets sector and 100.54% lower than that of the Financials industry. The return on equity for all Canada stocks is 88.29% lower than that of the firm.
Big Pharma Split Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Big Pharma's current stock value. Our valuation model uses many indicators to compare Big Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Big Pharma competition to find correlations between indicators driving Big Pharma's intrinsic value. More Info.Big Pharma Split is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers . At this time, Big Pharma's Return On Equity is very stable compared to the past year. Comparative valuation analysis is a catch-all model that can be used if you cannot value Big Pharma by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Big Pharma's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Big Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Big Pharma's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Big Pharma could also be used in its relative valuation, which is a method of valuing Big Pharma by comparing valuation metrics of similar companies.Big Pharma is currently under evaluation in return on equity category among its peers.
Big Pharma Current Valuation Drivers
We derive many important indicators used in calculating different scores of Big Pharma from analyzing Big Pharma's financial statements. These drivers represent accounts that assess Big Pharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Big Pharma's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 16.8M | 13.3M | 18.9M | 22.0M | 16.7M | 13.9M | |
| Enterprise Value | 26.9M | 22.5M | 32.3M | 31.0M | 26.8M | 22.6M |
Big Fundamentals
| Return On Equity | -0.0363 | ||||
| Return On Asset | -0.0069 | ||||
| Profit Margin | (2.01) % | ||||
| Operating Margin | 0.51 % | ||||
| Current Valuation | (9.41 M) | ||||
| Shares Outstanding | 1.13 M | ||||
| Number Of Shares Shorted | 100 | ||||
| Price To Book | 0.95 X | ||||
| Price To Sales | 46.87 X | ||||
| Revenue | 311.76 K | ||||
| Gross Profit | 5.56 M | ||||
| EBITDA | (139.68 K) | ||||
| Net Income | (645.35 K) | ||||
| Total Debt | 10.3 M | ||||
| Book Value Per Share | 13.99 X | ||||
| Cash Flow From Operations | 11.86 M | ||||
| Short Ratio | 1.19 X | ||||
| Earnings Per Share | 0.99 X | ||||
| Target Price | 2.0 | ||||
| Beta | 0.88 | ||||
| Market Capitalization | 15.04 M | ||||
| Total Asset | 26.53 M | ||||
| Annual Yield | 0.09 % | ||||
| Net Asset | 26.53 M | ||||
| Last Dividend Paid | 1.24 |
About Big Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Big Pharma Split's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Big Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Big Pharma Split based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | -10 M | -10.6 M | |
| Total Revenue | 311.8 K | 296.2 K | |
| Cost Of Revenue | 308.6 K | 343.6 K | |
| Sales General And Administrative To Revenue | 1.07 | 1.13 | |
| Revenue Per Share | 0.26 | 0.24 | |
| Ebit Per Revenue | (0.45) | (0.43) |
Pair Trading with Big Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Big Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Big Pharma will appreciate offsetting losses from the drop in the long position's value.Moving together with Big Stock
Moving against Big Stock
The ability to find closely correlated positions to Big Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Big Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Big Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Big Pharma Split to buy it.
The correlation of Big Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Big Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Big Pharma Split moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Big Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Big Stock
Big Pharma financial ratios help investors to determine whether Big Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Big with respect to the benefits of owning Big Pharma security.